Sugi Predict

Sugi Predict / Compounds / SCHEMBL19666780

SCHEMBL19666780

SCHEMBL19666780

CCCCCc1c(Br)c(O)c(Br)c(O)c1C(=O)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.40
▸ ALOX15 P16050 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ NR1H2 P55055 1/20 0.39
▸ NR1H3 Q13133 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.39
▸ ESR1 P03372 3/20 0.39
▸ HTT P42858 2/20 0.38
▸ PKM P14618 2/20 0.38
▸ GAA P10253 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8400705 0.98 ALDH1A1 (0.40) MAPTALOX15TSHRHSD17B10CA12
SCHEMBL8402794 0.98 ALDH1A1 (0.40) MAPTALOX15TSHRHSD17B10CA12
SCHEMBL19666785 0.91 CA12 (0.42) MAPTALOX15TSHRHSD17B10CA12
SCHEMBL29225453 0.88 ALOX5 (0.37) HSD17B10ALDH1A1ESR1GAAKDM4E
SCHEMBL9396779 0.85 PTPN1 (0.53) NR1H2NR1H3KDM4ESMN1; SMN2CYP3A4
SCHEMBL28548859 0.81 SMN1; SMN2 (0.40) MAPTTSHRHSD17B10CA12CA1
SCHEMBL19680128 0.79 NR1H2 (0.51) MAPTALOX15TSHRHSD17B10CA12
SCHEMBL31752771 0.78 ALOX5 (0.41) HSD17B10ALDH1A1ESR1HTTGAA
SCHEMBL19680127 0.77 NR1H2 (0.45) MAPTALOX15TSHRHSD17B10CA12
SCHEMBL4383570 0.77 CA12 (0.47) MAPTALOX15TSHRHSD17B10CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865780-A Total synthesis process of cannabidiol 山东新华制药股份有限公司 2024-04-12 — — CN disclosed
US-10399920-B2 Crystalline form of cannabidiol S&B Pharma, Inc. (US) 2019-09-03 — — US disclosed
US-10399920-B2 Crystalline form of cannabidiol S&B Pharma, Inc. (US) 2019-09-03 — — US disclosed
US-20170349518-A1 Crystalline Form of Cannabidiol S&B PHARMA, INC., DBA NORAC PHARMA 2017-12-07 — — US disclosed
US-20170349518-A1 Crystalline Form of Cannabidiol S&B PHARMA, INC., DBA NORAC PHARMA 2017-12-07 — — US disclosed
US-20170349518-A1 Crystalline Form of Cannabidiol S&B PHARMA, INC., DBA NORAC PHARMA 2017-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349518-A1 Crystalline Form of Cannabidiol CNR1, CNR2, CALCOCO2 MAPT 68/4885ALOX15 3031/4885TSHR 3227/4885
US-10399920-B2 Crystalline form of cannabidiol CNR1, CNR2, CALCOCO2 MAPT 68/4885ALOX15 3031/4885TSHR 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.